What is the price target for LVTX stock?
7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.
LAVA Therapeutics NV (LVTX) Forecast, Price Target & Analyst Ratings
NASDAQ:LVTX • NL0015000AG6
Current stock price
1.74 USD
-0.07 (-3.87%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LAVA Therapeutics NV (LVTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 26, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.40
Upside
-19.69%
From current price of $1.74 to mean target of $1.40, Based on 7 analyst forecasts
Low
$1.25
Median
$1.40
High
$1.58
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for LVTX. The average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
LVTX was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about LVTX.
In the previous month the buy percentage consensus was at a similar level.
LVTX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-05 | Jefferies | Downgrade | Buy -> Hold |
| 2025-08-05 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-05-15 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-12-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-12 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-12-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-08-21 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-23 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-09 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-04-13 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-10-25 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-27 | SVB Leerink | Maintains | Outperform |
| 2022-09-15 | JMP Securities | Initiate | Market Outperform |
| 2022-05-18 | SVB Leerink | Maintains | Outperform |
| 2021-11-16 | SVB Leerink | Maintains | Outperform |
| 2021-08-17 | SVB Leerink | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 26, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- -89.43%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
LVTX is expected to report earnings on 3/26/2026. The consensus EPS estimate for the next earnings is -0.27 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 19.39M 287.80% | 6.769M -65.09% | 11.982M 77.01% | -100.00% | ||||||||
| EBITDA YoY % growth | -34.06M 22.22% | -42.782M -25.61% | -29.226M 31.69% | -33.253M -13.78% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -34.84M 21.44% | -43.394M -24.55% | -29.693M 31.57% | -27.765M 6.49% | -34.362M -23.76% | -34.485M -0.36% | -20.105M 41.70% | -20.613M -2.52% | -21.121M -2.47% | -22.02M -4.25% | -23.067M -4.76% | |
| Operating Margin | -179.68% | -641.07% | -247.81% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -1.25 88.76% | -1.59 -27.21% | -0.93 41.51% | -0.86 7.87% | -0.51 40.48% | -0.38 26.00% | -0.26 32.43% | -0.26 | -0.07 72.24% | 0.10 243.37% | 0.21 110.55% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.27 -89.43% | -0.21 -64.77% | -0.20 36.25% | -0.19 28.22% | -0.17 34.62% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.752M 73.89% | -8.054M -6.14% | -8.134M -7.28% | -8.216M -14.00% | -8.298M -7.04% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.82%
EPS Next 5 Year
11.53%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-14.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
LAVA Therapeutics NV / LVTX Forecast FAQ
Can you provide the upcoming earnings date for LAVA Therapeutics NV?
LAVA Therapeutics NV (LVTX) will report earnings on 2026-03-26, after the market close.
What are the consensus estimates for LAVA Therapeutics NV (LVTX) next earnings?
The consensus EPS estimate for the next earnings of LAVA Therapeutics NV (LVTX) is -0.27 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for LAVA Therapeutics NV (LVTX) stock?
The consensus rating for LAVA Therapeutics NV (LVTX) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.